Kaseta Michael sold $1.5M of LQDA

Kaseta Michael (CFO and COO) sold 20,430 shares of Liquidia Corp (LQDA) at an average of $71.51 ($71.39–$71.52, $1.46M total) across 2 trades on 2026-07-13 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Kaseta Michael
Published Jul 15, 2026, 12:08 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Jul 15, 2026, 12:30 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$LQDA
Neutral
high confidence
Mentioned
$LQDA
Relevance
5/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$LQDANeutralLow
01

Why it matters

The newest fact is the CFO/COO’s open-market sale of 20,430 shares at $71.39 to $71.52, executed under a pre-arranged 10b5-1 plan.

02

Market read

Traders may monitor for follow-on insider activity, but this specific disclosure is unlikely to change valuation absent accompanying fundamental news.

03

What to watch

The article does not provide context on total insider holdings, prior sale cadence, or whether other insiders also sold/bought around the same period.

Relevance 5/10Novelty 3/10Timing: after-hours/next-session context from a Form 4 filed 2026-07-14 for trades dated 2026-07-13

Background

The article is a SEC Form 4 insider transaction disclosure for Liquidia Corp (LQDA).

Company-level read

Ticker impact

$LQDANeutralHigh confidence
Context

Liquidia CFO and COO Kaseta Michael sold 20,430 shares in open-market trades at about $71.51 on 2026-07-13 under a 10b5-1 plan.

Expected impact

Likely limited immediate price impact; any reaction would be sentiment-driven rather than fundamental.

Evidence & confidence

The filing is a Form 4 insider transaction with a stated 10b5-1 pre-arranged plan, which typically reduces the signal of new negative information.

Market effects

No clear sector read-through; this is company-specific insider selling without operational or guidance changes.

None indicated.

None indicated.

Counterpoint

Insider sales can be driven by diversification, taxes, or planned liquidity needs, especially when executed under a 10b5-1 plan.

Key entities

  • Liquidia Corp

    Company whose insider transaction is disclosed on Form 4.

  • Kaseta Michael

    CFO and COO who sold shares in open-market trades.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$LQDAMed

LQDA Q3 Earnings Beat Estimates on Robust Yutrepia Sales

Liquidia Corporation (LQDA) reported Q3 2026 earnings of 80 cents per share, exceeding estimates. Revenue surged 314.6% YoY to $225.3M, driven by strong Yutrepia sales. The company settled litigation with United Therapeutics, incurring a $389.7M charge. LQDA stock gained 7.37% post-announcement. Management remains optimistic about Yutrepia's growth and pipeline advancements.

$LQDAMed

Wells Fargo raises Liquidia stock price target on improved outlook

Wells Fargo raised its price target for Liquidia Technologies (LQDA) to $40 from $33, citing improved demand outlook. The stock has gained 85% over the past year. LQDA reported Q3 revenue of $225.3M, beating estimates, but posted a GAAP EPS loss of $2.64 due to a settlement charge. Analysts from BTIG and Jefferies also raised their price targets, expressing confidence in the company's growth prospects.

$LQDAHighAI 8/10

Liquidia (LQDA) Q3 2026 Earnings Call Transcript

Liquidia (LQDA) reported Q3 2026 net product sales of $222.7M, up 31%. PAH diagnoses drove growth, with 70% of prescriptions in September. October saw record shipments post-settlement. Referrals held steady, and prescriber base expanded. YUTREPIA's flexibility supports market share gains in PAH. Financials show strong revenue growth, with adjusted EBITDA at $140.5M. The company plans to fund operations without raising capital.

$LQDAMed

Liquidia Q3 Earnings Call Highlights

Liquidia (LQDA) reported Q3 adjusted EBITDA of $140.5M, up sequentially, with $396.1M in cash. The company faces a $389.7M settlement, payable by April 2027. Liquidia plans clinical trials for YUTREPIA and L606, with data expected in 2027-2029. Management affirmed no capital raise is needed and no royalties to United Therapeutics post-settlement.